Daniel P. Murphy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniel P. Murphy has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Scott Reule
Department of Medicine, Medical School, University of Minnesota, Minneapolis, MN
3 shared publicationsAreef Ishani
Department of Medicine, Medical School, University of Minnesota, Minneapolis, Minnesota, USA; Section of Nephrology, Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota, USA
2 shared publications- Julian Wolfson
Division of Biostatistics and Health Data Science University of Minnesota Minneapolis Minnesota USA
2 shared publications - Kirsten L. Johansen
Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota
2 shared publications Paul E. Drawz
Department of Medicine, Medical School, University of Minnesota, Minneapolis, MN
2 shared publications- Paul Englund Drawz
Division of Renal Diseases and Hypertension, University of Minnesota Medical School, Minneapolis, Minnesota
2 shared publications
Latest Publications
- Open Access
- 23 September 2025
- Published by Elsevier in Kidney Medicine
- Vol. 7 (11) , 101119
Factors Associated With Proteinuria Assessment After Acute Kidney Injury Among US Veterans
- 23 September 2025
- Published by Elsevier in Kidney Medicine
- Vol. 7 (11) , 101119
Open AccessFactors Associated With Proteinuria Assessment After Acute Kidney Injury Among US Veterans
- Open Access
- 28 August 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (8) , 1254-1255
To Hold or Not to Hold, that is the Newest Sodium-Glucose Cotransporter-2 Inhibitor Question
- 28 August 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (8) , 1254-1255
Open AccessTo Hold or Not to Hold, that is the Newest Sodium-Glucose Cotransporter-2 Inhibitor Question
- 27 April 2024
- Published by Elsevier in Kidney International
- Vol. 106 (1) , 126-135
A cohort study of sodium-glucose cotransporter-2 inhibitors after acute kidney injury among Veterans with diabetic kidney disease
- 27 April 2024
- Published by Elsevier in Kidney International
- Vol. 106 (1) , 126-135
A cohort study of sodium-glucose cotransporter-2 inhibitors after acute kidney injury among Veterans with diabetic kidney disease
- Open Access
- 30 January 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (3) , 335-343
Kidney Outcomes with Sodium–Glucose Cotransporter-2 Inhibitor Initiation after AKI among Veterans with Diabetic Kidney Disease
Key Points: Post-AKI sodium–glucose cotransporter-2 inhibitor use was associated with a reduced risk for progression of CKD and for recurrent AKI among veterans with diabetic kidney disease even after accounting for recovery from the index AKI. A minority of Veterans with diabetic kidney disease received a sodium–glucose cotransporter-2 inhibitor after having had AKI during the study period. Background: The effect of sodium–glucose cotransporter-2 inhibitor (SGLT2i) on kidney function after AKI is unknown. Methods: The study population was drawn from a retrospective cohort of Veterans with diabetes mellitus type 2 (DM2) and proteinuria. The study exposure was time-varying use of SGLT2i after an index AKI hospitalization. The two study outcomes were time to (1) a sustained decrease in eGFR over at least 3 months to 2 and ≥30% below a post-AKI–updated eGFR and (2) recurrent hospitalization with AKI. AKI was defined as a rise in serum creatinine concentration to ≥50% above a moving outpatient creatinine baseline. DM2 was defined by ≥2 billing codes related to DM2 before the index AKI; proteinuria was defined by the most recent albuminuria, proteinuria, or urinalysis test. Veterans were required to have a baseline eGFR and an eGFR 3–12 months after the index AKI hospitalization ≥30 ml/min per 1.73 m2. Results: Ten thousand thirty-six Veterans met study inclusion criteria. Two thousand seven hundred and ninety-four (28%) received a SGLT2i. Seven hundred and seventy-five (8%) had CKD progression, and 1816 (18%) had recurrent AKI over a median follow-up of 1.8 and 1.7 years, respectively, which began 1 year after the index AKI hospitalization. SGLT2i use was associated with lower risk for CKD progression (adjusted hazard ratio 0.72 [95% confidence interval, 0.57 to 0.91]) and for recurrent AKI (adjusted hazard ratio 0.75 [95% confidence interval, 0.65 to 0.88]). Conclusions: SGLT2i use was associated with a lower risk for CKD progression and for recurrent AKI among those with diabetic kidney disease and recent AKI.
- 30 January 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (3) , 335-343
Open AccessKidney Outcomes with Sodium–Glucose Cotransporter-2 Inhibitor Initiation after AKI among Veterans with Diabetic Kidney Disease
Key Points: Post-AKI sodium–glucose cotransporter-2 inhibitor use was associated with a reduced risk for progression of CKD and for recurrent AKI among veterans with diabetic kidney disease even after accounting for recovery from the index AKI. A minority of Veterans with diabetic kidney disease received a sodium–glucose cotransporter-2 inhibitor after having had AKI during the study period. Background: The effect of sodium–glucose cotransporter-2 inhibitor (SGLT2i) on kidney function after AKI is unknown. Methods: The study population was drawn from a retrospective cohort of Veterans with diabetes mellitus type 2 (DM2) and proteinuria. The study exposure was time-varying use of SGLT2i after an index AKI hospitalization. The two study outcomes were time to (1) a sustained decrease in eGFR over at least 3 months to 2 and ≥30% below a post-AKI–updated eGFR and (2) recurrent hospitalization with AKI. AKI was defined as a rise in serum creatinine concentration to ≥50% above a moving outpatient creatinine baseline. DM2 was defined by ≥2 billing codes related to DM2 before the index AKI; proteinuria was defined by the most recent albuminuria, proteinuria, or urinalysis test. Veterans were required to have a baseline eGFR and an eGFR 3–12 months after the index AKI hospitalization ≥30 ml/min per 1.73 m2. Results: Ten thousand thirty-six Veterans met study inclusion criteria. Two thousand seven hundred and ninety-four (28%) received a SGLT2i. Seven hundred and seventy-five (8%) had CKD progression, and 1816 (18%) had recurrent AKI over a median follow-up of 1.8 and 1.7 years, respectively, which began 1 year after the index AKI hospitalization. SGLT2i use was associated with lower risk for CKD progression (adjusted hazard ratio 0.72 [95% confidence interval, 0.57 to 0.91]) and for recurrent AKI (adjusted hazard ratio 0.75 [95% confidence interval, 0.65 to 0.88]). Conclusions: SGLT2i use was associated with a lower risk for CKD progression and for recurrent AKI among those with diabetic kidney disease and recent AKI.
- 7 August 2023
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 34 (10) , 1721-1732
Renin–Angiotensin–Aldosterone System Blockade after AKI with or without Recovery among US Veterans with Diabetic Kidney Disease
Significance Statement: Among patients with CKD, optimal use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers after AKI is uncertain. Despite these medications' ability to reduce risk of mortality and other adverse outcomes, there is concern that ACEi/ARB use may delay recovery of kidney function or precipitate recurrent AKI. Prior studies have provided conflicting data regarding the optimal timing of these medications after AKI and have not addressed the role of kidney recovery in determining appropriate timing. This study in US Veterans with diabetes mellitus and proteinuria demonstrated an association between ACEi/ARB use and lower mortality. This association was more pronounced with earlier post-AKI ACEi/ARB use and was not meaningfully affected by initiating ACEis/ARBs before versus after recovery from AKI. Background: Optimal use of angiotensin-converting enzyme inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) after AKI is uncertain. Methods: Using data derived from electronic medical records, we sought to estimate the association between ACEi/ARB use after AKI and mortality in US military Veterans with indications for such treatment (diabetes and proteinuria) while accounting for AKI recovery. We used ACEi/ARB treatment after hospitalization with AKI (defined as serum creatinine ≥50% above baseline concentration) as a time-varying exposure in Cox models. The outcome was all-cause mortality. Recovery was defined as return to ≤110% of baseline creatinine. A secondary analysis focused on ACEi/ARB use relative to AKI recovery (before versus after). Results: Among 54,735 Veterans with AKI, 31,146 deaths occurred over a median follow-up period of 2.3 years. Approximately 57% received an ACEi/ARB P for interaction with time <0.001). In secondary analysis, compared with those with neither recovery nor ACEi/ARB use, risk of mortality was lower in those with recovery without ACEi/ARB use (aHR, 0.90; 95% CI, 0.87 to 0.94), those without recovery with ACEi/ARB use (aHR, 0.69; 95% CI, 0.66 to 0.72), and those with ACEi/ARB use after recovery (aHR, 0.70; 95% CI, 0.67 to 0.73). Conclusions: This study demonstrated lower mortality associated with ACEi/ARB use in Veterans with diabetes, proteinuria, and AKI, regardless of recovery. Results favored earlier ACEi/ARB initiation.
- 7 August 2023
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 34 (10) , 1721-1732
Renin–Angiotensin–Aldosterone System Blockade after AKI with or without Recovery among US Veterans with Diabetic Kidney Disease
Significance Statement: Among patients with CKD, optimal use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers after AKI is uncertain. Despite these medications' ability to reduce risk of mortality and other adverse outcomes, there is concern that ACEi/ARB use may delay recovery of kidney function or precipitate recurrent AKI. Prior studies have provided conflicting data regarding the optimal timing of these medications after AKI and have not addressed the role of kidney recovery in determining appropriate timing. This study in US Veterans with diabetes mellitus and proteinuria demonstrated an association between ACEi/ARB use and lower mortality. This association was more pronounced with earlier post-AKI ACEi/ARB use and was not meaningfully affected by initiating ACEis/ARBs before versus after recovery from AKI. Background: Optimal use of angiotensin-converting enzyme inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) after AKI is uncertain. Methods: Using data derived from electronic medical records, we sought to estimate the association between ACEi/ARB use after AKI and mortality in US military Veterans with indications for such treatment (diabetes and proteinuria) while accounting for AKI recovery. We used ACEi/ARB treatment after hospitalization with AKI (defined as serum creatinine ≥50% above baseline concentration) as a time-varying exposure in Cox models. The outcome was all-cause mortality. Recovery was defined as return to ≤110% of baseline creatinine. A secondary analysis focused on ACEi/ARB use relative to AKI recovery (before versus after). Results: Among 54,735 Veterans with AKI, 31,146 deaths occurred over a median follow-up period of 2.3 years. Approximately 57% received an ACEi/ARB P for interaction with time <0.001). In secondary analysis, compared with those with neither recovery nor ACEi/ARB use, risk of mortality was lower in those with recovery without ACEi/ARB use (aHR, 0.90; 95% CI, 0.87 to 0.94), those without recovery with ACEi/ARB use (aHR, 0.69; 95% CI, 0.66 to 0.72), and those with ACEi/ARB use after recovery (aHR, 0.70; 95% CI, 0.67 to 0.73). Conclusions: This study demonstrated lower mortality associated with ACEi/ARB use in Veterans with diabetes, proteinuria, and AKI, regardless of recovery. Results favored earlier ACEi/ARB initiation.
- Open Access
- 16 October 2021
- Published by Elsevier in Kidney Medicine
- Vol. 4 (1) , 100376
Acute Kidney Injury in the Outpatient Setting: Developing and Validating a Risk Prediction Model
- 16 October 2021
- Published by Elsevier in Kidney Medicine
- Vol. 4 (1) , 100376
Open AccessAcute Kidney Injury in the Outpatient Setting: Developing and Validating a Risk Prediction Model
- Open Access
- 1 April 2021
- Published by Elsevier in Kidney International Reports
- Vol. 6 (4) , S123-S124
POS-290 MANAGEMENT OF HEART FAILURE IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A RETROSPECTIVE ANALYSIS OF 1,861 ADMISSIONS TO ST GEORGE'S HOSPITAL, LONDON
- 1 April 2021
- Published by Elsevier in Kidney International Reports
- Vol. 6 (4) , S123-S124
Open AccessPOS-290 MANAGEMENT OF HEART FAILURE IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A RETROSPECTIVE ANALYSIS OF 1,861 ADMISSIONS TO ST GEORGE'S HOSPITAL, LONDON